According to the Zhitong Finance App, Maibo Pharmaceutical-B (02181.HK) announced interim results for the six months ended June 30, 2026. The Group's revenue was RMB 398 million, up 45.1% year on year; profit attributable to shareholders was RMB 31.36 million, up 982.1% year on year; profit per share.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.